Shelter Pharma FY26 Revenue at Rs 73.13 Crore, PAT at Rs 9.03 Crore

Revenue grew by 44.35% YoY to Rs 73.13 crore, while Profit After Tax rose 24.73% to Rs 9.03 crore.

Reader Takeaway: Strong top-line growth offset by a governance oversight in related party transactions requiring shareholder ratification.

What just happened

Shelter Pharma released its 19th Annual Report for FY 2025-26, showcasing significant financial expansion. The company’s revenue climbed to Rs 73.13 crore from Rs 50.66 crore in the previous year. Profit After Tax (PAT) reached Rs 9.03 crore, up from Rs 7.24 crore. EPS grew modestly to Rs 6.57.

Why this matters

The company’s ability to scale revenue by over 44% suggests strong demand for its herbal and veterinary healthcare products. However, the report includes a secretarial audit finding regarding non-compliance with SEBI Regulation 23(1). This involves a failure to classify certain trade advances as material related party transactions (RPTs) after regulatory changes in April 2025.

What changes now

Shelter Pharma is seeking shareholder approval at its September 29, 2026, Annual General Meeting to ratify these past transactions. Additionally, the company is seeking approval for fresh material RPTs with entities including Gandhi Brothers and Shelter Pharmacy Pvt Ltd, each capped at Rs 25 crore. Dr. Vinita Shivraj Gadhavi will be regularized as an Independent Director.

Risks to watch

Investors should track the effectiveness of the company’s new internal compliance tracking mechanisms. Management attributed the RPT lapse to a bona fide interpretation gap, but future governance transparency remains a focus area. Raw material price volatility and market competition also remain ongoing operational risks.

Context metrics

Shelter Pharma currently operates across 14 Indian states and maintains a presence in over 10 countries. EBITDA margins for the year stood at 12.74 crore, reflecting steady operational execution.